Global, regional and national burden of maternal haemorrhage (2000–2021) and projections to 2050 in 204 countries and territories Authors: Mulat Ayele, Bereket Duko, Tenaw Tiruye, Paul R Ward, Lillian Mwanri, Gavin Pereira, Tegene Atamenta Kitaw, Biruk Beletew Abate, Eyob Shitie Lake, Abebaw Alamrew, Aynalem Yetwale, Gizachew Yilak, Befkad Derese Tilahun, Chalie Mulugeta, Tadele Emagneneh, Amanuel Tesfay Gebremedhin Published: 2026 ABSTRACT AbstractObjectiveTo estimate the global, regional and national burden of maternal haemorrhage (2000–2021) and its 2050 projections in 204 countries and territories.DesignThis study systematic analysis of the burden of maternal haemorrhage sourced data from the Global Burden of Disease (GBD) 2021 study. We estimated the incidence, mortality, disability-adjusted life years (DALYs), years lived with disability (YLDs) and years of life lost (YLLs) due to maternal haemorrhage. Changes in the burden from 2000 to 2021 were computed using AAPC. To detect statistically notable changes in the trends of maternal haemorrhage metrics between 2000 and 2021, Joinpoint regression analysis using the Joinpoint Regression Programme was conducted. We also projected mortality rates, YLDs and YLLs through to 2050 using maps and trends generated by the GBD Foresight visualisation tool.ResultsGlobally, the incidence of maternal haemorrhage among women aged 15–49 years declined from 881.98 per 100 000 reproductive aged women (95% uncertainty interval (UI) 687.01 to –1150.23) in 2000 to 714.00 (95% UI 556.97 o t908.54) in 2021, with an average annual percentage change (AAPC) of –0.91 (–1.37 to –0.49). Similar downward trends were observed for maternal deaths, DALYs, YLDs and YLLs attributable to maternal haemorrhage, with AAPCs of –3.78 (–4.39 to –3.18), –4.68 (–4.83 to –4.55), –1.21 (–1.54 to –0.89) and –4.80 (–5.10 to –4.52), respectively. Sub-Saharan Africa, particularly Western Sub-Saharan Africa, recorded the highest burden in 2021, which is almost 300 times higher than in Western Europe. Elevated rates of mortality, DALYs and YLDs were also evident in Sierra Leone, Chad, Niger, Mali, Nigeria, Burkina Faso, Central African Republic, Somalia and South Sudan in 2021 and projections for 2050. However, the high-income Asia Pacific region had the lowest incidence, DALYs and YLDs at 151.32 (109.63–203.68), 2.21 (1.72–2.86) and 0.87 (0.46–1.38) per 1 00 000 women, respectively. Australasia recorded the lowest maternal death count and YLLs attributed to maternal haemorrhage at 0.69 (0.50–0.90) and 0.56 (0.41–0.74) per 1 00 000 women, respectively.ConclusionWhile the global burden of maternal haemorrhage has declined over time, significant regional and national inequities persist. Even though the 2050 projections show improvement in the burden of maternal haemorrhage, there is also regional and national variation in the rate of decrease in maternal haemorrhage burden. Targeted, context-specific interventions are urgently needed to reduce maternal haemorrhage-related mortality and morbidity. STRENGTH AND LIMITATION OF THE STUDY Uses Global Burden of Disease 2021 data from 204 countries and territories, integrating multiple data sources within a standardised modelling framework. Uses Global Burden of Disease 2021 data from 204 countries and territories, integrating multiple data sources within a standardised modelling framework. Country-specific projections of maternal haemorrhage burden to 2050 were generated using the Global Burden of Diseases Foresight visualisation tool and restricted to countries with non-zero projected maternal haemorrhage rates. Country-specific projections of maternal haemorrhage burden to 2050 were generated using the Global Burden of Diseases Foresight visualisation tool and restricted to countries with non-zero projected maternal haemorrhage rates. Estimates may be influenced by variability in data completeness and quality across regions, particularly in settings with limited maternal health surveillance systems. Estimates may be influenced by variability in data completeness and quality across regions, particularly in settings with limited maternal health surveillance systems. The 2050 projections may not fully capture disruptions to maternal healthcare services and access associated with the COVID-19 pandemic. The 2050 projections may not fully capture disruptions to maternal healthcare services and access associated with the COVID-19 pandemic. The projection estimates are subject to uncertainty due to external factors not incorporated in the modelling framework including geopolitical instability, reduction in international health funding, conflict and population shifts due to climate change. The projection estimates are subject to uncertainty due to external factors not incorporated in the modelling framework including geopolitical instability, reduction in international health funding, conflict and population shifts due to climate change. Introduction According to the WHO, maternal death is defined as the death of a woman during pregnancy or within 42 days of the termination of pregnancy, from any cause related to or aggravated by pregnancy or its management, but not from accidental or incidental causes, regardless of the duration and site of the pregnancy.1 The global maternal mortality ratio (MMR) was estimated at 223 maternal deaths per 100 000 live births in 2020 and 197 per 100 000 live births in 2023, indicating a significant deviation from the trajectory required to achieve Sustainable Development Goal 3 (SDG 3), target 3.1. This target aims to lower the global MMR to <70 per 100 000 live births by 2030.2 Achieving this goal will require an annual reduction rate of nearly 15%.2 3 In 2023, approximately 87% (225 000) of the estimated worldwide maternal deaths occurred in Sub-Saharan Africa (SSA) and Southern Asia. Of these, about 70% occurred in SSA alone (182 000 deaths) and 17% in Southern Asia (43 000 deaths).4 Maternal haemorrhage is a major obstetric complication that substantially increases maternal morbidity and mortality.5 It includes antepartum haemorrhages such as vaginal bleeding after 20 weeks of gestation, bleeding related to early pregnancy and other bleeding due to neoplasms. Postpartum haemorrhage is defined as blood loss >500 mL following vaginal delivery or 1000 mL following caesarean delivery.6 Maternal haemorrhage accounts for 20% of maternal deaths worldwide.7 The contribution of maternal haemorrhage to maternal deaths varies by region: it accounts for 13% of maternal deaths in developed countries, 10% in the USA, 21% in Latin America, 31% in Asia and 28.8% in Africa.810 Although death from maternal haemorrhage is largely preventable and has been substantially reduced in high-income countries (HICs), women in low-income and middle-income countries (LMICs) continue to bear a disproportionate burden. The majority of maternal deaths due to haemorrhage occur in SSA and South Asia.3 This discrepancy reflects disparities in the social determinants of health and the implementation of preventive and treatment measures between high-income and low-income countries.9 In Africa, maternal deaths from haemorrhage are linked to inadequate resources, a shortage of skilled birth attendants, poor maternal nutrition including micronutrient deficiencies in pregnancy,11 deliveries in under-equipped facilities and limited access to essential obstetric care supplies such as safe blood transfusions. For instance, the availability of safe blood transfusion items in the African region averaged around 60% between 2015 and 2018.10 Furthermore, in most high-income and upper-middle-income countries, approximately 99% of all deliveries are attended by a skilled midwife, physician or nurse. Nonetheless, only 73% of deliveries in low-income countries and 84% in LMICs are attended by qualified healthcare providers.12 In Asia, high maternal mortality attributed to haemorrhage is also linked to a shortage of haemostasis and thrombosis specialists. For example, the region has only 0.15 International Society of Thrombosis and Haemostasias members per million people compared with 8.1 per million in Australia and New Zealand.9 Inconsistent implementation of effective strategies for preventing and managing haemorrhage, combined with systemic political, economic and health system issues such as understaffing and inadequate blood bank capacity, has contributed to persistently high and unacceptable levels of maternal deaths related to haemorrhage.1315 Therefore, global efforts to prevent and manage maternal haemorrhage are essential to achieving SDG 3, target 3.1, and reducing maternal mortality. A comprehensive understanding of both the current burden and future projections of maternal haemorrhage is crucial to developing effective prevention and treatment strategies. Despite its significant contribution to maternal deaths worldwide, limited studies have examined the global burden of maternal haemorrhage since the COVID-19 pandemic.6 Up-to-date data post-2019 are lacking, even though COVID-19 likely influenced the burden of maternal haemorrhage.16 At the height of the pandemic in 2021, essential health services were disrupted in 92% of countries and the Universal Health Coverage (UHC) service coverage index showed no improvement since 2019, indicating that about 4.5 billion people remained without full access to essential health services.17 Previous GBD assessments of maternal haemorrhage have focused primarily on incidence and short-horizon APC projections.18 In contrast, this study quantified incidence, mortality, disability-adjusted life years (DALYs), years lived with disability (YLDs) and years of life lost (YLLs) alongside incidence for women aged 15–49 years. Moreover, this study estimates breakpoint-aware trends (average annual percentage change (AAPC)) from 2000 to 2021 and extends national projections to 2050 to foreground equity gaps and health system implications. The findings will help inform more effective prevention and treatment strategies, ultimately contributing to the reduction of maternal mortality worldwide. Methods Study design and data source The study is an ecological, time-trend analysis using data sourced from the Global Burden of Disease (GBD) 2021 Study, spanning from 2000 to 2021, to estimate the incidence, mortality, DALYs, YLDs and YLLs associated with maternal haemorrhage and project future trends through to 2050. In this study, rates were expressed per 1 00 000 women of reproductive age (15–49 years) across 204 countries, including 95% uncertainty intervals (UIs), in accordance with standard GBD reporting practice, allowing comparability across locations with varying fertility levels. GBD 2021 estimated key maternal haemorrhage metrics in women aged 15–49 years across 204 countries and territories, grouped into 21 regions and seven super-regions. GBD regions are made up of countries and territories that are geographically close and epidemiologically similar.19 These regions are then grouped into super-regions based on the cause of death patterns. The full GBD location hierarchy is shown in online supplemental file 1 and table 1. All data were obtained from the Global Health Data Exchange (GHDx), hosted by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington (http://ghdx.healthdata.org/gbd-results-tool). Table 1Global and regional incidence rate of maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UILocationcountryGlobal and regional incidence rates of maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UI2000 (95% UI)2021 (95% UI)AAPC (95% UI)Global881.98 (687.01 to 1150.23)714.00 (556.97 to 908.54)−0.91* (−1.37 to −0.49)Central Europe, Eastern Europe and Central Asia544.34 (399.42 to 732.13)579.49 (447.89 to 751.35)0.47 (−1.68.29 to 2.56) Central Asia586.91 (435.27 to 796.45)534.84 (405.14 to 715.36)−0.28 (−1.84 to 1.23) Central Europe676.55 (500.42 to 887.60)654.54 (519.84 to 822.85)−0.13 (−0.42 to 0.15) Eastern Europe459.95 (328.05 to 624.88)561.89 (420.80 to 752.92)1.21 (−2.46 to 4.85)High income466.83 (371.34 to 581.25)414.54 (332.53 to 513.17)−0.62 (−1.66 to 0.39) Australasia689.21 (622.67 to 759.65)654.00 (497.67 to 856.26)−0.3558 (−1.7032 to 0.9249) Asia Pacific167.99 (124.67 to 226.67)151.32 (109.63 to 203.68)−0.35 (−1.41 to 0.67) North America512.08 (390.69 to 666.39)406.00 (333.58 to 490.56)−1.18 (−3.04 to 0.62) Southern Latin America976.35 (763.38 to 1221.15)751.82 (593.50 to 974.72)−1.14*(−1.65 to −0.65) Western Europe479.95 (381.76 to 592.99)448.06 (349.97 to 569.00)−0.43 (−1.09 to 0.19)Latin America and Caribbean848.11 (680.86 to 1059.55)686.33 (544.05 to 871.35)−1.01* (−1.36 to −0.69)Andean Latin America1691.57 (1299.47 to 2163.57)1233.26 (957.90 to 1553.37)−1.44* (−1.87 to −1.02)Caribbean756.72 (586.42 to 995.94)583.95 (450.04 to 752.04)−1.15* (−1.67 to −0.67)Central Latin America1098.67 (880.33 to 1370.87)856.55 (670.49 to 1096.12)−1.08* (−1.41 to −0.77)Tropical Latin America396.30 (328.28 to 483.34)357.65 (281.11 to 456.38)−0.84 (−4.56 to 2.80)North Africa and Middle East969.06 (737.25 to 1285.68)608.08 (463.50 to 809.63)−2.04* (−3.28 to −0.86)South Asia1150.91 (851.35 to 1529.72)583.44 (431.27 to 781.65)−3.25* (−3.75 to −2.77)Southeast Asia, East Asia and Oceania529.45 (396.91 to 699.78)533.91 (404.64 to 679.55)0.48 (−2.05 to 2.94)East Asia390.45 (276.54 to 532.06)438.76 (321.62 to 566.16)1.39 (−3.55 to 6.29)Oceania1224.64 (919.53 to 1610.16)1032.35 (778.80 to 1361.58)−0.78* (−1.13 to −0.45)Southeast Asia860.88 (663.04 to 1103.22)696.32 (538.71 to 886.18)−3.25* (−3.75 to −2.77)Sub-Saharan Africa2360.18 (1833.40 to 3099.30)1652.46 (1267.38 to 2151.81)−1.69* (−2.16 to −1.23)Central Sub-Saharan Africa2877.10 (2225.31 to 3657.32)1810.59 (1381.32 to 2352.77)−2.17* (−3.19 to −1.19)Eastern Sub-Saharan Africa2478.21 (1876.58 to 3281.20)1624.93 (1229.02 to 2164.80)−2.01* (−2.33 to −1.70)Southern Sub-Saharan Africa600.66 (478.60 to 762.16)545.29 (420.94 to 710.48)−0.47 (−1.97 to 0.98)Western Sub-Saharan Africa2605.52 (2031.82 to 3385.26)1834.48 (1410.29 to 2367.75)−1.65* (−2.16 to −1.16)*indicates that the average annual percentage change (AAPC) is significantly different from zero at the alpha level of 0.05. UI, uncertainty interval. Global and regional incidence rate of maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UI indicates that the average annual percentage change (AAPC) is significantly different from zero at the alpha level of 0.05. UI, uncertainty interval. The GHDx, managed by IHME, offers a comprehensive repository of global health data, encompassing information on disease burdens, health risk factors and healthcare utilisation patterns across a wide range of countries and regions. GBD estimates are derived from multiple data sources, including disease burden (vital registries, scientific literature, vital statistics, disease surveillance and reports) and health service use (administrative data, household surveys, civil registration systems and health service utilisation records).20 Data completeness and reliability vary across regions; countries with well-established civil registration and vital statistics systems contribute more direct empirical data to the estimates, whereas low-resource settings with limited surveillance infrastructure rely more heavily on modelled approximations. Overall, the GBD 2021 study comprises 1020 data sources for fatal maternal haemorrhage and 258 data sources for nonfatal maternal haemorrhage (online supplemental file 1 and figure 1). Based on the actual data points and relevant predictive covariates, the final and missing data are further estimated using various statistical models for fatal and nonfatal burden estimates (online supplemental file 1 and table 2). Map showing comparison of maternal deaths due to maternal haemorrhage per 100,000 women aged 15–49 years at 2021 and 2050. (a) National maternal death rate map due to maternal haemorrhage in women aged 15–49 at 2021. (b) National maternal death rate map due to maternal haemorrhage in women aged 15–49 years at 2050. Table 2Global and regional burden of maternal death count due to maternal haemorrhage in women aged 15–49 years (2000–2021), with AAPC and 95% UILocationcountryGlobal and regional burden of maternal death count due to maternal haemorrhage in women aged 15–49 years (2000–2021), with AAPC and 95% UI2000 (95% UI)2021 (95% UI)AAPC (95% UI)Global102701.01 (93 743.39 to 112729.36)46 344.93 (38 790.83 to 55 740.44)−3.78* (−4.39 to −3.18)Central Europe, Eastern Europe and Central Asia342.38 (300.1 to 385.14)105.33 (88.11 to 125.01)−5.50* (−6.18 to −4.84) Central Asia186.36 (162.6 to 211.86)76.78 (61.50 to 94.46)−4.22* (−4.55 to-3.91) Central Europe43.63 (37.04 to 50.11)8.64 (7.22 to 10.23)−7.14* (−8.99 to −5.40) Eastern Europe112.39 (91.55 to 133.26)19.92 (15.73 to 24.93)−7.91* (−12.55 to −3.32)High income184.20 (160.76 to 206.25)80.89 (67.86 to 93.95)−3.73* (−6.03 to −1.51) Australasia2.07 (1.58 to 2.64)0.69 (0.5 to 0.9)−4.68* (−7.06 to −2.34) Asia Pacific37.40 (31.28 to 44.85)9.01 (6.97 to 11.33)−6.46* (−7.52 to-5.45) North America39.2 (30.74 to 49.48)29.53 (22.76 to 38.16)−1.42* (−2.50 to −0.39) Southern Latin America66.27 (52.91 to 81.04)26.44 (19.63 to 34.7)−3.98 (−8.86 to 0.94) Western Europe39.23 (34.72 to 43.95)15.23 (13.34 to 17.24)−4.37* (−6.97 to −1.89)Latin America and Caribbean2779.89 (2543.44 to 3061.17)1448.66 (1183.22 to 1755.37)−3.14* (−3.60 to −2.71)Andean Latin America854.37 (728.22 to 993.58)993.58 (259.76 to 493.71)−4.07* (−5.85 to −2.34)Caribbean475.56 (355.43 to 621.19)450.53 (285.98 to 653.74)−0.49 (−2.90 to 1.85)Central Latin America1023.18 (921.59 to 1139.46)415.18 (338.12 to 510.83)−4.28* (−6.67 to −1.94)Tropical Latin America426.78 (366.02 to 494.96)221.21 (179.73 to 264.58)−3.11* (−3.36 to −2.87)North Africa and Middle East5401.89 (4366.03 to 6595.104)2793.84(2005.3 to 3843.08)−3.10* (−4.81to −1.45)South Asia49 985.37(43 985.39 to 55 781.68)11 532.99 (9365.131 to 14453)−6.93* (−8.14 to −5.76)Southeast Asia, East Asia and Oceania14 313.68 (12 437.07 to 16 306.39)4164.08 (3378.587 to 5238.312)−5.81* (−6.47 to −5.18)East Asia2803.28 (2285.11 to 3391.66)297.63 (212.21 to 410.47)−10.39*(−12.27 to 8.63)Oceania228.29 (152.09 to 313.93)283.06 (186.83 to 398.95)1.16*(0.05 to 2.22)Southeast Asia11 282.1 (9611.68 to 13 055.35)3583.39 (2881.69 to 4673.08)−5.38*(−5.64 to −5.13)Sub-Saharan Africa29 693.64 (25 250.07 to 34 659.11)26 219.14 (21 034.69 to 32 318.86)−0.59 (-2.11 to 0.88)Central Sub-Saharan Africa3689.83 (3006.40 to 4507.01)3289.58 (2285.78 to 4589.75)−0.50 (-5.77 to 4.83)Eastern Sub-Saharan Africa11 431.82 (9948.83 to 13 152.08)6632.45 (5300.33 to 8138.942)−2.70*(−4.34 to −1.12)Southern Sub-Saharan Africa513.44 (416.94 to 620.14)355.05 (250.92 to 497.48)−2.73 (-10.23 to 4.96)Western Sub-Saharan Africa14 058.56 (10 885.61 to 18 027.69)15 942.05(12 022.93 to 21 318.69)0.69 (-1.51 to 2.84)*indicates that the average annual percentage change (AAPC) is significantly different from zero at the alpha level of 0.05.UI, uncertainty interval. Global and regional burden of maternal death count due to maternal haemorrhage in women aged 15–49 years (2000–2021), with AAPC and 95% UI indicates that the average annual percentage change (AAPC) is significantly different from zero at the alpha level of 0.05. UI, uncertainty interval. For this analysis, we used the GHDx ‘Search’ interface with the following criteria: GBD estimates (cause of death or injury), measures (incidence, mortality, DALYs, YLDs and YLLs), metrics (number, percentage and rate), cause (maternal haemorrhage), geographic location (global, regional and sub-regional), age group (15–49 years), sex (female) and time frame (2000 to 2021). Based on the GBD 2021 hierarchical classification system, maternal haemorrhage (c_367) is categorised as a level 4 cause within the broader maternal and neonatal disorders category. In the GBD hierarchy, level 4 denotes the most detailed level in the GBD cause hierarchy, identifying specific disease types for analytical purposes, and should not be seen as a measure of clinical severity.21 Within the GBD framework, maternal haemorrhage includes postpartum haemorrhage, antepartum haemorrhage and placenta-related bleeding disorders, corresponding to ICD-10 codes O44–O46, O67 and O72.20 22 Postpartum haemorrhage is clinically defined by the WHO as blood loss ≥500 mL after vaginal delivery or ≥1000 mL after caesarean delivery, while antepartum haemorrhage refers to vaginal bleeding occurring at or beyond 20 weeks of gestation prior to labour onset.20 21 However, GBD estimates are derived from ICD-coded vital registration systems, hospital records, surveys and verbal autopsy data rather than direct clinical measurement of blood loss. Therefore, the operational definition in this study reflects cause-of-death classification systems consistent with the GBD framework rather than bedside diagnostic thresholds. Statistical analysis Based on available data inputs and modelled covariates, the GBD 2021 study estimated maternal haemorrhage burden using a standardised analytical framework. Covariates considered in the modelling process included in-facility delivery (proportion), skilled birth attendance (proportion), age-specific and sex-specific summary exposure value for unsafe sanitation, log-transformed neonatal mortality ratio, maternal education and the Healthcare Access and Quality Index.20 22 For fatal outcomes such as death and YLLs, the GBD study applied the Cause of Death Ensemble Modelling, which incorporates spatiotemporal Gaussian process regression components to model cause-specific mortality across locations and years.22 For non-fatal outcomes, including incidence, DALY and YLDs, the study used DisMod-MR 2.1, a Bayesian meta-regression tool that ensures internal consistency between epidemiological parameters (incidence, prevalence, remission and excess mortality) across age groups, time periods and geographic locations.20 These modelling approaches generated annual estimates of maternal haemorrhage burden among women of reproductive age across 204 countries and territories from 2000 to 2021. Uncertainty was propagated throughout the modelling process using 1000 posterior draws, with 95% UIs defined by the 2.5th and 97.5th percentiles of the draw distribution (online supplemental file 1 and table 2).20 22 To estimate the burden of maternal haemorrhage, we examined metrics including incidence rate, mortality count, DALYs rate, YILDs rate and YLLs rate—each with corresponding 95% UIs—specifically among women aged 15–49 years. In this study, the incidence, DALYs, YILDs and YLLs were estimated using rates per 100 000 reproductive aged women, whereas mortality was measured by count or number. To detect statistically notable changes in the trends of maternal haemorrhage metrics between 2000 and 2021, Joinpoint regression analysis using the Joinpoint Regression Programme (V.5.4.0, National Cancer Institute) was performed.23 This technique enables us to pinpoint moments in time when there are significant shifts in the data’s rate of change. The regression model fits several linear segments to the data, each segment representing a unique trend. Initially, the analysis began with the minimum number of joinpoints (0 joinpoints, indicating a single straight line) and then assessed whether the addition of extra joinpoints (up to a maximum of 5) significantly enhanced the model’s fit. Joinpoints, where the trend’s slope alters, were identified to investigate periods of acceleration or deceleration in the burden of maternal haemorrhage. The annual percentage change (APC) was used to capture the rate of change in each segment, utilising the formula: APC = (exp(β) − 1) × 100%, where β represents the regression coefficient of the log-linear model ln y = β*x. Following this, the AAPC was computed by averaging the APC identified across all segments, considering the duration of each segment.6 24 The AAPC provides a comprehensive measure of the overall rate of change in the burden of maternal haemorrhage over the study period, accommodating any fluctuations in trends. The 95% UI of the AAPC was calculated to illustrate the variability of the trend. An increasing trend in the metrics was suggested when the AAPC and the lower boundary of the 95% UI were positive, whereas a decreasing trend was suggested when the AAPC and the upper boundary of the 95% UI were negative. If neither condition is fulfilled, it suggests a stable trend, indicating that rates remain relatively consistent during the given period.25 26 The significance of change was also determined at a p-value of 0.05. To predict the projected burden of maternal haemorrhage for 2050, autoregressive integrated moving average (ARIMA) models were used. Projections were performed separately for each country using annual time-series data. Because the study population comprised women of reproductive age (15–49 years), all analyses were restricted to this demographic group. Estimates were sex-specific (female only) and age-standardised using the standard population structure provided by the GBD Study to ensure comparability across countries and over time. Prior to model fitting, time-series stationarity was assessed using unit root testing, and differencing was applied where appropriate. Model identification was guided by inspection of autocorrelation (ACF) and partial ACF (PACF) plots. Competing ARIMA (p, d and q) specifications were compared using Akaike information criterion (AIC) and Bayesian information criterion, with the model demonstrating the best fit selected for forecasting. Diagnostic checks included examination of residual autocorrelation (Ljung–Box Q test) and residual normality using Q–Q plots to confirm adequacy of model assumptions. The model having lowered AIC was selected for forecasting. However, given the decreasing pattern in the burden of maternal haemorrhage, countries and regions are anticipated to reach zero or negative maternal haemorrhage cases at varying projected timelines when utilising the ARIMA model. As a result, a 2050 projection was undertaken for countries with a substantial number of maternal haemorrhage cases. The associated deaths, YLDs and DALYs were projected using maps and patterns to provide insights into the future trends of maternal health outcomes in these regions. GBD foresight visualisation maps were employed for each country using the link https://vizhub.healthdata.org/gbd-foresight/. This study adheres to the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER). This checklist details the data sources, analytical methods, modelling strategies and procedures used to generate the estimates and projections, ensuring transparency and reproducibility of our findings27 (online supplemental file 2). Patients or the public involvement In this study, there is no patient or public involvement. Results Global level of maternal haemorrhage burden Globally, the incidence of maternal haemorrhage decreased from 881.98 per 100 000 (95% UI 687.01 to 1150.23) to 714.00 per 100 000 (95% UI 556.97 to 908.54) with an AAPC of −0.91 (95% UI −1.37 to −0.49) from 2000 to 2021 (table 1 and online supplemental figure S1). In 2021, approximately 46 344.93 (95% UI 38 790.83 to 55 740.44) mothers aged 15–49 died due to maternal haemorrhage, reflecting a significant decrease from 102 701.01 (95% UI 93 743.39 to 112 729.36) in 2000 with a significant AAPC of −3.78 (95% UI −4.39 to −3.18) (table 2 and online supplemental figure S2). Additionally, the global DALYs of women aged 15–49 due to maternal haemorrhage have been decreasing over time from 2000 to 2021, dropping from 407.37 per 1 00 000 cases (95% UI 374.41 to 446.49) in 2000 to 150.07 per 100 000 (95% UI 126.61 to 179.00) in 2021 with an AAPC of −4.68 (95% UI −4.83 to −4.55). The rate of decrease varies during different time periods, with the most significant decline observed between 2012 and 2015. This trend suggests consistent negative changes in the global DALYs attributed to maternal haemorrhage in this age group over the years, as indicated by the AAPC values (table 3 and online supplemental figure S3). Table 3Global and regional DALY rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UILocation countryGlobal and regional DALY rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UI2000 (95% UI2021 (95% UI)AAPC (95% UI)Global407.37 (374.41 to 446.49)150.07 (126.61 to 179.00)−4.68* (−4.83 to -4.55)Central Europe, Eastern Europe and Central Asia22.76 (19.81 to 26.02)10.69 (8.46 to 13.31)−3.47* (−4.04 to −2.92) Central Asia62.60 (55.03 to 70.68)24.31 (19.30 to 29.29)−4.41* (−4.79 to -4.05) Central Europe12.94 (10.65 to 15.92)6.45 (4.55 to 8.64)−3.08* (−4.27 to −1.92) Eastern Europe14.67 (12.11 to 17.40)6.10 (4.47 to 8.20)−3.99* (−6.23 to -1.83)High income6.74 (5.53 to 8.03)6.00 (4.93 to 7.18)−2.35* (−2.80 to −1.92) Australasia5.44 (4.01 to 7.02)3.68 (2.22 to 5.53)−1.77* (−2.60 to −0.89) Asia Pacific5.77 (4.83 to 6.90)2.21 (1.72 to 2.86)−4.39* (−4.87 to −3.92) North America5.44 (4.06 to 7.05)4.17 (3.25 to 5.47)−1.32*(−1.95 to −0.71) Southern Latin America32.61 (26.14 to 39.31)12.99 (9.99 to 17.24)−4.04* (−7.26 to −0.85) Western Europe4.59 (3.51 to 5.80)3.08 (2.12 to 4.22)−1.95* (−2.38 to −1.51)Latin America and Caribbean137.52 (125.26 to 151.21)58.38 (49.51 to 70.01)−4.08* (−4.47 to −3.72)Andean Latin America431.58 (368.78 to 498.90)126.91 (94.14 to 171.88−5.72* (−7.34 to −4.15)Caribbean270.04 (203.69 to 354.40)225.76 (144.44 to 327.16)−1.06 (-3.33 to 1.14)Central Latin America121.87 (109.86 to 134.80)41.08 (33.78 to 49.49)−5.13* (−6.11 to −4.17)Tropical Latin America55.30 (47.65 to 63.43)24.89 (20.73 to 29.56)−3.79* (−3.95 to −3.62)North Africa and Middle East313.95 (255.49 to 381.75)110.80 (80.79 to 149.23)−4.83* (−5.88 to −3.82)South Asia989.53 (875.59 to 1103.94)154.88 (126.56 to 191.67)−8.64* (−9.22 to −8.08)Southeast Asia, East Asia and Oceania168.84 (147.62 to 191.51)50.73 (41.74 to 63.58)−5.63* (−7.56 to −3.74)East Asia48.26 (39.96 to 58.46)7.92 (6.06 to 10.28)−8.40 (−9.80 to −7.01)Oceania683.21 (462.06 to 931.52)507.56 (337.20 to 706.96)−1.29* (−2.20 to −0.43)Southeast Asia457.59 (390.67 to 526.74)119.38 (96.41 to 154.12)−6.24* (−7.06 to −5.45)Sub-Saharan Africa1166.24 (998.00 to 1355.83)571.35 (458.66 to 701.48)−3.33* (−4.90 to −1.82)Central Sub-Saharan Africa1303.71 (1065.84 to 1576.19)596.43 (419.15 to 811.78)−3.60 (−8.66 to 1.52)Eastern Sub-Saharan Africa1158.52 (1008.73 to 1325.72)374.73 (303.50 to 374.73)−5.38* (−7.09 to −3.72)Southern Sub-Saharan Africa180.17 (146.36 to 216.89)99.84 (71.88 to 137.82)−3.70 (−10.77 to 3.53)Western Sub-Saharan Africa1416.15 (1101.59 to 1798.70)825.56 (627.38 to 1098.07)−2.44* (−4.67 to −0.26)*indicates that the average annual percentage change (AAPC) is significantly different from zero at the alpha level of 0.05. DALYS, disability-adjusted life years; UI, uncertainty interval. Global and regional DALY rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UI indicates that the average annual percentage change (AAPC) is significantly different from zero at the alpha level of 0.05. DALYS, disability-adjusted life years; UI, uncertainty interval. In 2000, the YLDs associated with maternal haemorrhage were 8.98 (95% UI 5.49 to 13.06) per 1 00 000 cases. This figure decreased to 6.89 (95% UI 4.16 to 10.24) per 100 000 in 2021 with an AAPC of −1.21 (95% UI −1.54 to −0.89) (table 4 and online supplemental figure S4). Table 4Global and regional YLD rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UILocationcountryGlobal and regional YLD rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UI2000 (95% UI)2021 (95% UI)AAPC (95% UI)Global8.98 (5.49 to 13.06)6.89 (4.16 to 10.24−1.21* (−1.54 to −0.89)Central Europe, Eastern Europe and Central Asia4.24 (2.48 to 6.35)4.41 (2.67 to 6.68)0.35 (−1.56 to 2.22) Central Asia6.46 (3.78 to 9.85)5.66 (3.30 to 8.74)−0.47 (−1.91 to 0.91) Central Europe4.72 (2.69 to 7.22)4.51 (2.63 to 6.70)−0.18 (−0.48 to 0.11) Eastern Europe3.24 (1.81 to 4.98)3.73 (2.15 to 5.77)0.90 (−2.54 to 4.31)High-income2.35 (1.35 to 3.53)2.12 (1.23 to 3.20)−0.53 (−1.55 to 0.47) Australasia3.31 (1.91 to 4.89)3.12 (1.67 to 5.07)−0.38 (−1.61 to 0.79) High-income Asia Pacific0.94 (0.54 to 1.46)0.87 (0.46 to 1.38)−0.20 (−1.18 to 0.75) High-income North America2.58 (1.48 to 3.90)2.14 (1.26 to 3.18)−0.94 (−3.12 to 1.19) Southern Latin America5.53 (3.14 to 9.05)4.21 (2.13 to 6.88)−1.15*(−1.76 to −0.58) Western Europe2.28 (1.31 to 3.46)2.15 (1.19 to 3.28)−0.39 (−1.17 to 0.35)Latin America and Caribbean6.24 (3.81 to 9.11)4.77 (2.84 to 7.08)−1.32* (−1.92 to −0.75)Andean Latin America12.79 (7.37 to 19.41)8.33 (4.90 to 12.76)−1.95* (−2.86 to −1.08)Caribbean7.57 (4.50 to 11.34)6.44 (3.87 to 10.01)−0.66 (−1.98 to 0.61)Central Latin America6.71 (4.01 to 9.85)4.91 (2.89 to 7.51)−1.41*(−1.64 to −1.19)Tropical Latin America3.88 (2.37 to 5.71)3.27 (1.93 to 4.91)−1.18 (−4.86 to 2.41)North Africa and Middle East9.31 (5.41 to 14.14)5.30 (3.11 to 8.02)−2.51* (−3.63 to −1.44)South Asia15.01 (9.00 to 22.60)7.42 (4.40 to 11.58)−3.36* (−3.75 to −2.99)Southeast Asia, East Asia and Oceania4.38 (2.53 to 6.45)3.95 (2.32 to 5.89)−0.11 (−-2.61 to 2.31)East Asia2.81 (1.57 to 4.29)2.70 (1.52 to 4.04)0.61 (−4.80 to 6.04)Oceania17.32 (9.78 to 28.14)13.01 (7.33 to 21.25)−1.21 (−2.80 to 0.33)Southeast Asia8.05 (4.80 to 11.92)6.06 (3.71 to 8.95)−1.31* (−1.84 to −0.81)Sub-Saharan Africa27.53 (16.79 to 40.88)18.39 (11.05 to 27.35)−1.92* (−2.09 to −1.75)Central Sub-Saharan Africa37.38 (22.37 to 56.59)20.40 (12.41 to 30.61)−2.84* (−3.81 to −1.91)Eastern Sub-Saharan Africa25.44 (15.27 to 38.00)15.37 (9.20 to 22.85)−2.43* (−2.61 to −2.26)Southern Sub-Saharan Africa6.09 (3.68 to 9.24)4.90 (2.94 to 7.42)−1.05 (−2.25 to 0.09)Western Sub-Saharan Africa32.90 (20.38 to 48.89)22.99 (13.78 to 34.56)−1.69* (−1.86 to −1.53)*indicates that the average annual percentage change (AAPC) is significantly different from zero at an alpha level of 0.05.UI, uncertainty interval. Global and regional YLD rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UI indicates that the average annual percentage change (AAPC) is significantly different from zero at an alpha level of 0.05. UI, uncertainty interval. Similarly, the YLLs attributed to maternal haemorrhage significantly decreased from 398.39 (95% UI 365.23 to 437.97) per 1 00 000 cases to 189.25 (95% UI 160.85 to 219.89) per 100 000, with an AAPC of −4.80 (95% UI −5.10 to −4.52) (table 5 and online supplemental figure S5). Table 5Global and regional burden of the YLL rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UILocationcountryGlobal and regional burden of the YLL rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UI2000 (95% UI)2021 (95% UI)AAPC (95% UI)Global398.39 (365.23 to 437.97)143.18 (120.11 to 172.10)−4.80* (−5.10 to −4.52)Central Europe, Eastern Europe and Central Asia18.52 (16.31 to 20.83)6.28 (5.24 to 7.46)−5.02* (−5.58 to −4.44) Central Asia56.14 (49.13 to 63.77)18.64 (14.87 to 22.97−5.17* (−5.73 to −4.62) Central Europe8.22 (6.99 to 9.44)1.94 (1.62 to 2.31)−6.35* (−8.29 to −4.52) Eastern Europe11.43 (9.33 to 13.572.38 (1.89 to 2.97−7.15* (−11.11 to −3.36)High income4.39 (3.83 to 4.92)1.94 (1.62 to 2.27)−3.70* (−1.59 to −5.89) Australasia2.13 (1.62 to 2.71)0.56 (0.41 to 0.74−5.70* (−8.45 to −3.04) Asia Pacific4.83 (4.03 to 5.78)1.34 (1.04 to 1.69)−5.88* (−6.58 to −5.17) North America2.86 (2.24 to 3.62)2.04 (1.57 to 2.63)−1.67* (−2.54 to −0.85) Southern Latin America27.08 (21.51 to 33.05)8.78 (6.53 to 11.51)−4.92* (−9.53 to −0.27) Western Europe2.31 (2.05 to 2.59)0.93 (0.81 to 1.06)−4.20* (−6.21 to −2.27)Latin America and Caribbean131.28 (119.92 to 144.20)53.60 (43.78 to 64.85)−4.26* (−4.64 to −3.90)Andean Latin America418.79 (356.09 to 487.53)118.58 (84.68 to 161.91)−5.90* (−7.52 to −4.33)Caribbean262.47 (195.58 to 343.75)219.32 (138.85 to 320.42)−1.07 (−3.41 to 1.20)Central Latin America115.16 (103.74 to 128.33)36.18 (29.41 to 44.26)−5.45* (−6.74 to −4.21)Tropical Latin America51.42 (43.94 to 59.7121.62 (17.48 to 25.79)−4.08* (−4.32 to −3.85)North Africa and Middle East304.64 (247.16 to 371.33)105.50 (75.54 to 144.41)−4.92* (−5.96 to -3.92)South Asia974.52 (858.13 to 1088.39)147.46 (119.88 to 184.60)−8.79* (−9.36 to −8.24)Southeast Asia, East Asia and Oceania164.46 (143.11 to 187.08)46.77 (37.92 to 58.91)−5.90* (−7.54 to −4.28)East Asia45.45 (37.11 to 54.99)5.23 (3.73 to 7.20)−10.05* (−11.79 to −8.34)Oceania665.89 (442.77 to 914.09)494.55 (327.36 to 693.66)−1.29* (−2.21 to −0.42)Southeast Asia449.54 (383.22 to 520.57)113.33 (90.63 to 149.08)−6.40* (−7.25 to −5.57)Sub-Saharan Africa1138.70 (968.52 to 1327.37)552.96 (442.69 to 681.85)−3.37* (−4.99 to −1.80)Central Sub-Saharan Africa1266.33(1030.22 to 1548.55)576.03 (399.21 to 790.31)−3.63 (−-8.79 to 1.61)Eastern Sub-Saharan Africa1133.07 (987.00 to 1302.31)359.36 (288.86 to 439.61)−5.47*(−7.23 to −3.76)Southern Sub-Saharan Africa174.08 (140.76 to 211.02)94.94 (67.26 to 132.56)−3.80 (−11.01 to 3.57)Western Sub-Saharan Africa1383.24 (1070.60 to 1773.54)802.58 (604.66 to 1071.90)−2.46* (−4.74 to −0.23)*indicates that the average annual percentage change (AAPC) is significantly different from zero at an alpha level of 0.05. UI, uncertainty interval. Global and regional burden of the YLL rates associated with maternal haemorrhage per 1 00 000 women aged 15–49 years (2000–2021), with AAPC and 95% UI indicates that the average annual percentage change (AAPC) is significantly different from zero at an alpha level of 0.05. UI, uncertainty interval. Regional level of maternal haemorrhage burden In 2000, Central SSA had the highest incidence rate of maternal haemorrhage, accounting for 2877.10 per 100 000 populations, while high-income Asia Pacific had the lowest rate, accounting for 167.99 per 100 000 individuals. In 2021, Western SSA recorded the highest incidence rate of maternal haemorrhage at 1834.48 per 100 000 individuals, while high-income Asia Pacific continued to have the lowest incidence rate at 157.32 per 100 000. Overall, all regions saw a decrease in the incidence of maternal haemorrhage from 2000 to 2021, except Central Europe, which increased by an AAPC of 0.47 (from 544.34 to 751.35), East Asia increased by 1.39 (from 390.45 to 438.76) and Eastern Europe increased by 1.21 (from 459.95 to 561.89) (table 1). In terms of maternal death count due to maternal haemorrhage, South Asia had the highest number of maternal deaths attributed to maternal haemorrhage, accounting for 49 985.68 maternal deaths in 2000. In contrast, Australasia had the lowest death count, with 2.07 maternal deaths. By 2021, SSA had the highest maternal death count, reporting 26 219 deaths, whereas Australasia maintained the lowest death count at 0.69 maternal deaths. Additionally, Oceania and Western SSA regions experienced an increased AAPC from 2000 to 2021, with increases of 1.16 and 0.69, respectively (table 2). Western SSA had the highest DALYs attributed to maternal haemorrhage in 2000, at 1416.15 (95% UI 1101.59 to 1798.70), which was almost 300 times higher than that in Western Europe, at 4.59 (95% UI 3.51 to 5.80). There is an almost 400-fold difference in DALYs attributed to maternal haemorrhage between Western SSA (1416.15) and high-income Asia Pacific (2.21) in 2021. Over time, DALYs in South Asia, East Asia and Southeast Asia had the highest AAPC from 2000 to 2021, −8.64, −8.40 and −6.24 respectively (table 3). The trend of YLDs rates decreased in most regions between 2000 and 2021. However, only East Asia and Eastern Europe saw a stable trend in YLD rates. In East Asia, the rate slightly changed from 2.81 (95% UI 1.57 to 4.29) in 2000 to 2.70 per 100 000 population (95% UI 1.52 to 4.04) in 2021, with an AAPC of 0.61 (95% UI −0.48 to 6.04). In Eastern Europe, the rate slightly changed from 3.24 (95% UI 1.81 to 4.98) in 2000 to 3.73 per 100 000 population (2.15 to 5.77) in 2021, with an AAPC of 0.9 (95% UI −2.54 to 4.31). In 2000, Central SSA had the highest YLDs at 37.38 (95% UI 22.37 to 56.59) per 100,000, whereas high-income Asia Pacific had the lowest YLDs at 0.94 (95% UI 0.54 to 1.46) per 100 000. Western SSA had the highest YLDs at 22.99 (95% UI 13.78 to 34.56), whereas high-income Asia Pacific maintained the lowest YLDs at 0.87 (95% UI 0.46 to 1.38) per 100 000 (table 4). Western SSA had the highest YLLs due to maternal haemorrhage over time, amounting to 1383.24 (95% UI 1070.60 to 1773.54) in 2000 and 802.58 (95% UI 604.66 to 1071.90) in 2021, with an AAPC of −2.46 (95% UI −4.74 to −0.23). In contrast, Australasia had the lowest YLLs over time, with 2.13 (95% UI 1.62 to 2.71) in 2000 and 0.56 (95% UI 0.41 to 0.74) in 2021, with an AAPC of −5.70 (95% UI −8.45 to −3.04) (table 5). National level of maternal haemorrhage burden and 2050 projection Maternal haemorrhage mortality among women aged 15–49 in certain regions of Africa was substantially higher than the global average in 2021. However, forecasts to 2050 suggest a potential decline in maternal haemorrhage deaths worldwide, with a trend towards lower death rates in most regions. Despite this overall improvement, there are still areas that exhibit higher rates of maternal haemorrhage deaths in 2050. In this study, the 2050 projections were generated solely for countries expected to have non-zero maternal haemorrhage rates by 2050, and given the overall, downward trajectory, regions will reach near-zero levels on different timelines. In 2021, the highest death rates (per 1 00 000 women aged 15–49) were observed in Sierra Leone (36.19; 95% UI 21.28 to 55.42), Chad (30.88; 95% UI 19.83 to 44.81) and Niger (19.69; 95% UI 11.97 to 29.8). The Central African Republic (17.46; 95% UI 10.22 to 27.82), Afghanistan (17.18; 95% UI 10.13 to 26.38) and South Sudan (13.43; 95% UI 7.44 to 21.8) were also elevated. Conversely, rates were notably low in Greenland (0.006; 95% UI 0.003 to 0.009), Australia 0.011; 95% UI 0.008 to 0.015), the USA (0.04; 95% UI 0.03 to 0.05) and China (0.08; 95% UI 0.06 to 0.11) (figure 1a and online supplemental figure S6). Looking forward to 2050, the projected maternal death rates due to maternal haemorrhage are expected to decrease to 8.16 deaths per 100 000 (95% UI 4.08 to 15.24) in Sierra Leone and 6.9 deaths per 100 000 (95% UI 3.11 to 13.01) in Chad. By 2050, the maternal death rates are anticipated to be 6.57 deaths per 100 000 (95% UI 2.89 to 12.99) in Niger, 5.11 (95% UI 2.23 to 10.2) in the Central African Republic, 4.84 (95% UI 1.64 to 12.28) in South Sudan and 3.96 (95% UI 1.9 to 7.29) in Nigeria (figure 1b and online supplemental figure S7). Among women aged 15–49, DALY rates attributable to maternal haemorrhage were markedly higher in SSA and parts of Central Asia compared with high-income countries. The highest burdens (DALYs per 100 000) were observed in Sierra Leone (2203; 95% UI 1304.36 to 3332.81), Chad (1883.2; 95% UI 1198.02 to 2730.44), Niger (1200.18; 95% UI 744.83 to 1735.04), Nigeria (1061.61; 95% UI 664.53 to 1566.26) and the Central African Republic (1030.57; 95% UI 625.08 to 1601.96). Elevated rates were also higher in Central Asia, notably Afghanistan (1.065; 95% UI 640.30 to 1618.58) (figure 2 and online supplemental figure S8). National disability-adjusted life year (DALY) rate map due to maternal haemorrhage in women aged 15–49 years at 2021. The 2050 projection also indicated that among women aged 15–49 years, DALYs per 100 000 attributable to maternal haemorrhage would be higher in Sierra Leone (495.92; 95% UI 246.97 to 928.18), Chad (443; 95% UI 201.63 to 830.45), Niger (421.18; 95% UI 190.44 to 805.17), Central African Republic (310; 95% UI 140.88 to 615.44), South Sudan (291.52; 95% UI 102.46 to 724.66) and Nigeria (262; 95% UI 126.32 to 481.26) (figure 3 and online supplemental figure S9). National disability-adjusted life year (DALY) rate map due to maternal haemorrhage in women aged 15–49 years at 2050 In 2021, higher YLDs per 1 00 000 women aged 15–49 due to maternal haemorrhage were also observed in SSA, particularly in Niger (36.36, 95% UI 20.13 to 56.13), Chad (35.94, 95% UI 20.07 to 59.57), Somalia (33.47, 95% UI 18.34 to 54.08), Mali (31.64, 95% UI 18.11 to 50.15) and Benin (30.19, 95% UI 17.79 to 48.28). Guinea-Bissau with 29.34 (95% UI 16.67 to 49.24), South Sudan with 25.15 (95% UI 14.08 to 39.65) and Burkina Faso with 24.72 (95% UI 14.35 to 38.44) also had high YLD rates. Liberia exhibited 24.59 YLDs per 100 000 population (95% UI 13.72–42.76), while Angola and Nigeria reported YLDs of 23.65 (95% UI 12.94 to 37.46) and 23 (95% UI 13.89 to 34.18), respectively (figure 4 and online supplemental figure S10). Map of national years lived with disability (YLD) rate due to maternal haemorrhage in women aged 15–49 years at 2021 The 2050 projection suggests that the YLD rate per 1 00 000 women aged 15–49 due to maternal haemorrhage is expected to decrease to 28.62 (95% UI 14.58 to 48.67) in Niger, 29.15 (95% UI 13.31 to 51.26) in Somalia, 28.55 (95% UI 12.87 to 50.78) in Chad, 24.29 (95% UI 11.57 to 43.38) in Burkina Faso and 20.46 (95% UI 8.83 to 37.7) in Mali. By 2050, the expected YLDs due to maternal haemorrhage are also projected to decrease to 19.48 per 100 000 (95% UI 7.43 to 37) in South Sudan and 18.41 (95% UI 8.53 to 33.43) in Nigeria (figure 5 and online supplemental figure S11). Map of national years lived with disability (YLD) rate due to maternal haemorrhage in women aged 15–49 years at 2050 Discussion The findings of this study highlight global, regional and national trends in maternal haemorrhage burden, particularly focusing on incidence, deaths, DALYs, YLDs and YLLs over the past two decades and its projections for 2050. In this study, the incidence of maternal haemorrhage decreased from 881.98 per 100 000 in 2000 to 714 per 100 000 in 2021, with an AAPC of −0.91 (−1.37 to −0.49). This finding is consistent with results of Fang et al.18 The decrease in maternal haemorrhage incidence highlights a reduction in new maternal haemorrhage cases due to advancements in maternal care during pregnancy, improvements in intrapartum care, utilisation of partographs and reductions in uterine atony, increased practice of active management of the third stage of labour, increased practice of evidence-based medicine, decreased obstructed labour, uterine rupture over time and increased of UHC.242831 Globally, maternal deaths, DALYs, YLDs and YLLs have also decreased over time with AAPCs of −3.78%, −4.68%, −1.21% and −4.8%, respectively. This reduction can be attributed to advancements in new technologies such as the pneumatic anti-shock garment, uterine balloon tamponade and improvements in surgeons’ skills in performing procedures such as uterine artery ligation, compression sutures and hysterectomies, all aimed at saving the lives of women, particularly in HICs.3235 Acknowledging the differences in the applicability of these technologies, LICs have also adopted these technologies for the management and prevention of maternal haemorrhage. Furthermore, in LICs, there has been an increase in institutional deliveries, antenatal and postnatal care, community awareness, a decrease in the reliance on traditional birth attendants over time and the provision of free or subsidised maternal health services.3639 These factors have played a significant role in reducing the burden of maternal haemorrhage, considering the variations in the rates of institutional deliveries, community awareness and the use of traditional birth attendants between HICs and LICs.39 The significant decrease in global DALYs was observed between 2012 and 2015. The observed decrease in DALYs between 2009 and 2015 is likely due to advancements in medical care and interventions for managing maternal haemorrhage likely contributed to a decrease in the severity and duration of disability caused by the condition, thus reducing the overall DALYs. During this time, active initiatives include Averting Maternal Death and Disability and the Skilled Care Initiative and the UN Secretary-General launched the first Global Strategy for Women’s and Children’s Health to catalyse interventions aimed at improving maternal and child health. These initiatives, among others, collectively aimed to reduce maternal haemorrhage–related mortality and disability by improving access to quality healthcare, strengthening health systems and addressing the social and economic factors that contribute to maternal deaths and disability.40 These initiatives collectively reduce the maternal DALYs by improving access to quality healthcare, strengthening health systems and addressing the social and economic factors that contribute to maternal deaths. From 2000 to 2021, maternal haemorrhage incidence declined globally but rose modestly in Central Europe (AAPC 0.47), Eastern Europe (1.21) and East Asia (1.39). Unlike other regions, these areas experienced significant disruptions to maternal health services during the COVID-19 pandemic, including reduced facility-based deliveries and delayed emergency interventions, which likely contributed to rising incidence. For example, in Europe and Northern America, the proportion of maternal deaths (proportion of maternal death (PM)) among women of reproductive age that are due to maternal causes increased from 0.6% to 0.7% between 2019 and 2021, and MMR increased from 11 in 2019 to 19 in 2021 which can be attributable to COVID-19 pandemic.12 41 While the global burden of maternal haemorrhage declined between 2000 and 2021, its burden remained significantly elevated in SSA, specifically in Western SSA when compared with high-income nations. In this study, the highest burden of maternal haemorrhage was reported in Western SSA countries including Sierra Leone, Niger, Chad and Nigeria in 2021 and in the 2050 projection. In 2021, a higher maternal mortality rate attributed to maternal haemorrhage was observed in Sierra Leone, Chad, Niger and the Central African Republic. The reported rates were 36.19, 30.88, 19.69 and 17.46 deaths per 100 000, respectively. Similarly, these countries would continue to experience higher death rates attributed to maternal haemorrhage by 2050, with projected rates of 8.16, 6.9, 6.57 and 5.11 deaths per 1 00 000 cases, respectively. This finding is aligned with the findings of research conducted SSA nations using national demographic health data, where Chad (44.7%), Niger (38.7%), the Democratic Republic of the Congo (34.8%), Nigeria (34.2%) and Sierra Leone (25.6%) had the highest proportions of maternal death associated with pregnancy.42 43 Similarly, in both 2021 and 2050 projection, higher DALYs were observed in Sierra Leone, Chad and Niger, whereas Niger (36.36 YLDs per 100 000), Chad (35.94 YLDs per 100 000), Somalia (33.47 YLDs per 100 000), Mali (31.64 YLDs per 100 000) and Burkina Faso (24.29 YLDs per 100 000) were the top countries with higher YLDs observed in 2021. By the 2050 projection, Somalia (29.15 YLDs per 100 000), Niger (28.62 YLDs per 100 000), Chad (28.55 YLDs per 100 000), Burkina Faso (24.29 YLLs per 100 000) and Mali (20.46 YLLs per 100 000) were the top-expected countries with higher YLDs. The higher burden of maternal haemorrhage in SSA, particularly in those western sub-Saharan countries, is linked to various factors such as limited resources, unskilled birth attendants, deliveries in poorly equipped facilities, lack of accountability resulting in poor-quality care and shortages of crucial obstetric care supplies like blood transfusions, heat-stable carbetocin, oxytocin, misoprostol and tranexamic acid.4447 For instance, in Zimbabwe, essential medicines were available only 48% of the time, compared with 47% in Malawi, 44% in Chad and Liberia, 43% in Zambia, 41% in Niger and even lower percentages in Eswatini (33%), Uganda (32%), Sierra Leone (31%), Burundi (29%), the Democratic Republic of the Congo (20%), Mauritania (19%) and South Sudan (14%). Furthermore, delays in reaching health facilities due to poor infrastructure, long distances to health facilities, delayed decisions to seek maternal care arising from inadequate health-seeking behaviours, delay in receiving appropriate care and a poor continuum of maternal care, contribute to the higher burden of maternal haemorrhage in SSA.10 48 The higher burden of maternal haemorrhage in these countries also can be attributed to the low coverage of essential maternal health services. These nations have a universal health service coverage index of <40,49 indicating significant gaps in access to crucial maternal healthcare services. The variations in maternal haemorrhage burden among countries can be attributed to variances in socio-economic, demographic, political instability, conflict and environmental factors across SSA. Furthermore, cultural misunderstandings, dietary restrictions, early marriages and customary birthing practices delay the pursuit and receipt of healthcare were the reasons for variation.10 50 51 The persistently high maternal haemorrhage burden in SSA, particularly in Western SSA, underscores the need for region-specific investments in the obstetric care system and the need for further in-depth examinations and analyses to gain a more detailed and comprehensive understanding. This will help in developing more effective policies and interventions to reduce the disparities in the burden of maternal haemorrhage among nations. For instance, scaling up comprehensive emergency obstetric and newborn care is crucial.5254 In areas where access to facility-based care is limited, strategies such as task-shifting and strengthening community health worker networks can play a vital role in improving maternal health outcomes.55 56 For example, a non-randomised two-group comparison study conducted in rural South Africa showed that mothers visited by community health workers had fewer depressive symptoms, attended more antenatal visits and relied less on traditional birth attendants.57 Addressing deficiencies in healthcare coverage is also imperative to effectively reduce maternal haemorrhage rates and improve maternal health outcomes in these regions. The higher projected burden of maternal haemorrhage implies a significant distance from the SDG 3.1 target timeline, which requires an annual MMR reduction rate of nearly 15% to achieve a global MMR <70 per 100 000 live births by 2030.2 Therefore, this necessitates collaborative efforts to reduce the burden of maternal haemorrhage by preventing the causes of haemorrhage and implementing timely and effective interventions in these countries. This can be achieved through targeted investments, improved healthcare infrastructure, enhanced emergency obstetric care, better training for healthcare providers and increased access to maternal health services. Strength and limitation of the study The major strength of the study is its utilisation of extensive, comprehensive data from the research,21 covering 204 countries and territories across a span of 21 years. This vast dataset facilitates robust global, regional and national estimations of maternal haemorrhage incidence, mortality, DALYs, YLDs and YLLs, providing valuable insights into long-term patterns. The incorporation of projected 2050 rates for maternal haemorrhage burden in a country will further assist policymakers and healthcare providers in formulating targeted strategies to diminish maternal haemorrhage-related fatalities, disabilities and premature deaths. Despite these strengths, the study possesses several limitations. First, although GBD 2021 provides a comprehensive review and assessment of global incidence, deaths and DALYs due to maternal haemorrhage, maternal haemorrhage might be under-reported, potentially leading to under-estimated figures. Second, although the trend of maternal haemorrhage is declining over time, different regions and nations have varying projected timelines to achieve zero maternal haemorrhage. Consequently, the 2050 projections were performed solely for nations expected to have non-zero maternal haemorrhage rates by 2050. Third, there is a notable variability in the quality of input data used in the GBD model. Data quality discrepancies across regions and countries can introduce inaccuracies and biases into the model’s outputs, potentially affecting the reliability of the projected figures. Additionally, country-specific misclassification issues can further impact the precision of the estimates, leading to potential underestimations or overestimations of the maternal haemorrhage burden in certain areas. Moreover, this study used an ecological, time–trend analysis using secondary GBD data, results the inability to infer causality. Fourth, the COVID-19 pandemic has introduced unprecedented challenges to healthcare systems worldwide, including disruptions to essential maternal health services. These COVID-19-related impacts, such as changes in service coverage, access to care, and healthcare priorities, may not be fully accounted for in the projections. Moreover, the 2050 projections are obviously open to external forces which we cannot predict: they are based on previous maternal haemorrhage rates, but our projections may change if external factors change, such as cutting United States Agency for International Development (USAID), political upheavals, wars and population shifts due to climate change. Additionally, the 2050 projection may lead to forecast uncertainty or potential model instability over long time horizons as the projection trend was done for several decades into the future. Therefore, when interpreting the 2050 figures on maternal haemorrhage burden, it is crucial to approach them with caution, considering these limitations and potential uncertainties in the data. Additionally, although the use of women of reproductive age as the denominator is consistent with GBD framework and enables cross-condition comparability, it limits direct comparability with maternal mortality ratio, which remains the primary international benchmark for maternal health monitoring. Lastly, this study does not illustrate the burden of maternal haemorrhage beyond 2021, as it is based on data.21 Thus, future research is needed to assess the factors influencing maternal haemorrhage and maternal health outcome. Conclusion Global rates of incidence, mortality, DALYs, YLDs and YLLs due to maternal haemorrhage declined from 2000 to 2001, yet substantial regional inequities persist. The burden is the highest in SSA, particularly in Western SSA, and the lowest in high-income regions. Several countries in Western and Central SSA such as Sierra Leone, Chad, Niger, Mali, Nigeria, Burkina Faso, the Central African Republic, Somalia and South Sudan show persistently high mortality and disability in 2021 and are projected to remain elevated by 2050. These findings underscore enduring health-system gaps and the need for targeted, context-specific strategies. Sustained progress will require coordinated action by governments and policy makers to fund and regulate essential obstetric services, healthcare providers to deliver reliable, evidence-based care, and researchers to generate implementation evidence and strengthen data system, ultimately facilitating reductions in maternal mortality and morbidity and addressing regional inequities. Supplementary material